163
Views
19
CrossRef citations to date
0
Altmetric
Review

Management of oropharyngeal candidiasis with localized oral miconazole therapy: efficacy, safety, and patient acceptability

, &
Pages 369-374 | Published online: 19 Jul 2011

References

  • PankhurstCLCandidiasis (oropharyngeal)Clin Evid (Online)200920091304 Epub 2009 Mar 18.19445752
  • WebbBCThomasCJWillcoxMDHartyDWKnoxKWCandida-associated denture stomatitis. Aetiology and management: a review. Part 3. Treatment of oral candidosisAust Dent J19984342442499775471
  • EllepolaANBSamaranayakeLPAntimycotic agents in oral candidosis: an overview: 1. Clinical variantsDent Update200027311111211411611218280
  • SamaranayakeLPOral mycoses in HIV infectionOral Surg Oral Med Oral Pathol19927321711801549312
  • LallaRVLatortueMCHongCHA systematic review of oral fungal infections in patients receiving cancer therapySupport Care Cancer201018898599220449755
  • Center for Drug Evaluation and Research, US Food and Drug Administration (FDA)Summary Review: application 22404Orig1s000; NDA22-404, Oravig (miconazole) for oropharyngeal candidiasisUS Center for Drug Evaluation and Research2010 Available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022404Orig1s000SumR.pdf. Accessed May 12, 2011.
  • Oravig [prescribing information]Woodcliff Lake, NJStrativa Pharmaceuticals, a division of Par Pharmaceutical, Inc2010 Available at: www.oravig.com/oral-thrush-once-daily/hcp-faqs.html. Accessed May 12, 2011.
  • ManfrediMMcCulloughMJPolonelliLIn vitro antifungal susceptibility to six antifungal agents of 229 Candida isolates from patients with diabetes mellitusOral Microbiol Immunol200621317718216626375
  • Luz PaniaguaGCMonroyEPNegreteEAVacaSPSusceptibility to 5-fluorocytosine, miconazole and amphotericin B of Candida albicans strains isolated from the throat of non-AIDS patientsRev Latinoam Microbiol2002442656817063773
  • HernáezMLGilCPlaJNombelaCInduced expression of Candida albicans multidrug resistance gene CDR1 in response to fluconazole and other antifungalsYeast19981465175269605502
  • IshamNGhannoumMAAntifungal activity of miconazole against recent Candida strainsMycoses201053543443719531099
  • GhannoumMAHerbertJIshamNRepeated exposure of Candida spp. to miconazole demonstrates no development of resistanceMycoses201034 [Epub ahead of print]
  • CardotJMChaumontCDubrayCConstantiniDAiacheJMComparison of the pharmacokinetics of miconazole after administration via a bioadhesive slow release tablet and an oral gel to healthy male and female subjectsBr J Clin Pharmacol200458434535115373926
  • ChaumontCCardotJMDubrayCConstantiniDAiacheJMSafety, acceptability, and adhesion of novel bioadhesive slow release tablet of miconazole in a phase I studyJournal de mycologie médicale2003131318
  • Van RoeyJHaxaireMKamyaMLwangaIKatabiraIComparative efficacy of topical therapy with a slow-release mucoadhesive buccal tablet containing miconazole nitrate versus systemic therapy with ketoconazole in HIV-positive patients with oropharyngeal candidiasisJ Acquir Immune Defic Syndr200435214415014722446
  • BensadounRJDaoudJEl GueddariBComparison of the efficacy and safety of miconazole 50 mg mucoadhesive buccal tablets with miconazole 500 mg gel in the treatment of oropharyngeal candidiasis: a prospective, randomized, single-blind, multicenter, comparative, phase III trial in patients treated with radiotherapy for head and neck cancerCancer2008112120421118044772
  • VazquezJAPattonLLJoelBRandomized, comparative, double-blind, double-dummy, multicenter trial of miconazole buccal tablet and clotrimazole troches for the treatment of oropharyngeal candidiasis: study of miconazole Lauriad® efficacy and safety (SMiLES)HIV clinical trials201011418619620974574
  • HamzaOJMateeMIBruggemannRJSingle-dose fluconazole versus standard 2-week therapy for oropharyngeal candidiasis in HIV-infected patients: a randomized, double-blind, double-dummy trialClin Infect Dis200847101270127618840077
  • VazquezJASkiestDJNietoLA multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDSClin Infect Dis20064281179118616575739
  • SkiestDJVazquezJAAnsteadGMPosaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infectionClin Infect Dis200744460761417243069
  • PappasPGKauffmanCAAndesDClinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of AmericaClin Infect Dis200948550353519191635
  • VillanuevaArathoonEGGotuzzoEBermanRSDiNubileMJSableCAA randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitisClin Infect Dis20013391529153511588698
  • SmithJAIs there a role for therapeutic drug monitoring of antifungal agents?Curr Infect Dis Rep200911643944619857383
  • KlotzSAOropharyngeal candidiasis: a new treatment optionClin Infect Dis20064281187118816575740
  • Who Technical Report Series, No. 920. The selection and use of essential medicines Available at: http://apps.who.int/medicinedocs/en/d/Js4881e/4.1.5.html#Js4881e.4.1.5. Accessed April 11, 2011.
  • SharonVFazelNOral candidiasis and angular cheilitisDermatol Ther201023323024220597942
  • Miconazole (Oravig) for oropharyngeal candidiasisMed Lett Drugs Ther2010 29;521352959621116234
  • 2010 RedbookMontvale, NJThomson Healthcare2010